Chugai Seiyaku Kabushiki Kaisha

Yukifumi Noda

Yasushi Murakami

Sakae Takaku

Shun-Ichi Hata

Hiroshi Nakakimura

Tomohiro Neichi

Takashi Mori

Hiroyuki Nabata

Tamotsu Yamazaki

Masuo Koizumi

Takashi Matsuno

Shigeyuki Kataoka

Shigeru Takanashi

Masamitsu Honda

Mitsutaka Yoshida

Hiroshi Matsushita

Yutaka Miura

Kazuo Sasahara

Yasuo Fujimura

Fumiaki Matsuura

4-aminopyridine derivatives represented by the general formula: ##STR1## [wherein R.sub.1 is a hydrogen atom, a hydroxyl group, a linear or branched lower alkyl group or a cycloalkyl group which may be substituted by a hydroxyl group, a lower alkoxy group, a lower alkyl or a cycloalkyl group which contains a carbonyl group, a morpholino group or a group --NH--B (where B is a lower alkyl group, a cycloalkyl group or a phenyl group); R.sub.2 and R.sub.3 which may be the same or different each represents a hydrogen atom, a lower alkyl group or a loweralkylcarbonyl group, or when taken together, form an azacycloalkyl group, a morpholino group or an N-methylpiperazinyl group together with the nitrogen atom; R.sub.4 and R.sub.5 each represents a hydrogen atom, or when taken together with the ring A, form a quinoline ring or a 5,6,7,8-tetrahydroquinoline ring, provided that when each of R.sub.1, R.sub.4 and R.sub.5 is a hydrogen atom, R.sub.2 and R.sub.3 are neither a hydrogen atom nor a methyl group at the same time, and when R.sub.1 is a hydrogen atom and R.sub.4 and R.sub.5 taken together with the ring A form a quinoline ring, R.sub.2 and R.sub.3 are neither a hydrogen atom nor an ethyl group at the same time], and an acid addition salts of said 4-aminopyridine derivatives. These compounds are useful as active ingredients in pharmaceutical compositions for improving psychoneural function, especially in the treatment of Alzheimer type dementia and promotion of mnemonic and learning performance.

3,4-diaminoquinoline and 3,4-diamino-5,6,7,8-tetrahydroquinoline

An agent for the treatment of disorders associated with cerebral ischemia which comprises N-(2-hydroxyethyl) nicotinamide nitrate as an active ingredient.

Therapeutic agent for the treatment of disorders associated with

Dibenzoxazepine derivatives of the formula: ##STR1## wherein R.sub.1, n, R.sub.2 and R.sub.3 are as defined in the description, process for preparing the same, pharmaceutical composition containing the same and method of treating diseases in circulatory organs administering the composition to a patient are disclosed. The compounds of the formula have lipid lowering activity, lipid peroxide lowering activity, blood sugar lowering activity and activity to inhibit the aggregation of platelets, and hence are useful as a medicine.

Dibenzoxazepine derivative, and pharmaceutical composition comprising

Novel compound, 1,2-bis(nicotinamido)propane and its pharmaceutically acceptable salts, a process for preparing the same and a pharmaceutical composition containing the same as an active ingredient are disclosed. The compound acts to prevent or spasmolyse cerebral vasospasms, to prevent cerebral apoplexy and to lower the lipoperoxide level in blood.

Nicotinamide derivative, process for preparing the same and

Growing community of inventors

Shizuoka, Japan

Yukifumi Noda